Horizon Therapeutics PLC
HZNP.OQ- Latest Trade
- trading lower82.45USD
- Change
- -0.31
- % Change
0.37%Negative
- As of Jul 6 2022. Values delayed up to 15 minutes
- Day Range
- 81.44 - 83.11
- 52-Week Range
- 78.76 - 120.32
- Previous Close
- 82.76
- Open
- 82.76
- Volume
- 491,213.00
- 3 Month Average Trading Volume
- 41.75
- Shares Out (Mil)
- 229.88
- Market Cap
- 19,025.21
- Forward P/E
- 14.04
- Dividend Yield
- -99,999.99
Key Statistics
1.73333333 mean rating - 15 analysts
- P/E Excl. Extra Items (TTM)
- 22.67
- Price To Sales (TTM)
- 5.05
- Price To Book (Quarterly)
- 3.94
- Price To Cash Flow (Per Share TTM)
- 15.34
- Total Debt/Total Equity (Quarterly)
- 53.32
- Long Term Debt/Equity (Quarterly)
- 52.99
- Return On Investment (TTM)
- 11.50
- Return On Equity (TTM)
- 10.39
2021 (millions USD)
About Horizon Therapeutics PLC
Company Information
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.
Address
Connaught House 1St Floor, 1 Burlington RoadDUBLIN,
D04 C5Y6
Ireland
Industry
Biotechnology & Drugs
Executive Leadership
- Timothy P. Walbert
- Chairman of the Board, President, Chief Executive Officer
- Aaron L. Cox
- Chief Financial Officer, Executive Vice President
- Sean M. Clayton
- Executive Vice President, General Counsel
- Michael A. DesJardin
- Executive Vice President - Technical Operations and Corporate Quality
- Vikram Karnani
- Executive Vice President, President - International
- Andy Pasternak
- Executive Vice President, Chief Strategy Officer
- Jeffrey W. Sherman
- Executive Vice President, Chief Medical Officer
- Elizabeth H.Z. Thompson
- Executive Vice President of Research and Development
- Michael G. Grey
- Lead Independent Director
- William Francis Daniel
- Independent Director
- Jeffrey Himawan
- Independent Director
- Susan M. Mahony
- Independent Director
- Gino Santini
- Independent Director
- James Samuel Shannon
- Independent Director
- H. Thomas Watkins
- Independent Director
- Pascale Witz
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,738.20 | 1.34%Negative |
| Copper | 645.40 | 0.90%Negative |
| Brent Crude Oil | 100.47 | 2.24%Negative |
| CBOT Soybeans | 1,578.25 | 0.19%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,845.08 | 0.36%Positive |
| Euro STOXX 50 | 3,421.84 | 1.85%Positive |
| FTSE 100 | 7,107.77 | 1.17%Positive |
| Nikkei 225 | 26,107.65 | 1.20%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes